伏硫西汀治疗首发重性抑郁症的临床疗效观察

目的]探讨伏硫西汀治疗首发重性抑郁症的临床疗效及安全性.方法]选择湖南省脑科医院的门诊及住院收治的123例重性抑郁症患者,按照随机数表法将其分为观察组(给予伏硫西汀10 m g/d治疗,n=61)和对照组(给予度洛西汀60 mg/d治疗,n=62),两组均治疗8周.以汉密尔顿抑郁量表(HAMD-17)评分作为主要疗效指标;以抑郁自评量表(SDS)、汉密尔顿焦虑量表(HAMA)、焦虑自评量表(SAS)评分作为次要疗效指标.安全性评估以副反应量表记录不良反应.结果]观察组显效率为75.4%,有效率为91.8%;对照组显效率为66.1%,有效率为88.7%.两组间显效率、有效率比较,差异无统计学意义(P>0.05).治疗后,两组HAMD评分均低于治疗前,差异有统计学意义(P<0.05);观察组治疗2周后HAMD评分低于对照组,差异有统计学意义(P<0.05).治疗8周后,两组HAMA总分及各因子评分、HAMD各因子分、SDS、SAS评分均低于治疗前,差异有统计学意义(P<0.05).观察组出现不良反应16例(26.2%),对照组出现不良反应18例(29.0%),两组不良反应发生率比较,差异无统计学意义(P>0.05).结论]伏硫西汀治疗抑郁症与度洛西汀疗效相当,伏硫西汀能较快的有效缓解抑郁症状,并能改善抑郁症患者的焦虑症状,安全性和耐受性好.

Clinical Effect of Vothixetine in the Treatment of First Major Depression

Objective]To analyze the safety and efficacy of vortioxetine in first episode major depressive disorder patients.Method]One hundred and twenty-three patients with major depression were randomly di-vided into two groups:the observation group(10 mg/D of vothixetine,n=61)and the control group(60 mg/D of duloxetine,n=62).The scores of HAMD 17 and SDS,HAMA and SAS were used as the main thera-peutic indexes.Adverse reactions were recorded by side effect scale in safety assessment.Results]The effec-tive rate of the observation group was 75.4%,the effective rate was 91.8%;the effective rate of the control group was 66.1%,the effective rate was 88.7%.There was no significant difference between the two groups in demonstrating efficiency and efficiency(P>0.05).After treatment,the HAMD scores of the two groups were lower than before treatment,the difference was statistically significant(P<0.05);the HAMD scores of the observation group were lower than that of the control group after 2 weeks of treatment,the difference was statistically significant(P0.05).Conclusion]The efficacy of vortioxetine in the treatment of depres-sion is similar to that of duloxetine.Vortioxetine can relieve the depressive symptoms quickly and effectively,and can improve the anxiety symptoms of patients with depression,with good safety and tolerance.